VectorBuilder-Pall Partnership Creates Viral Vector Optimization Center
VectorBuilder Inc. and Pall Corporation are establishing the VectorBuilder-Pall Center for Gene Therapy to optimize adherent cell-based GMP manufacturing of viral vectors for cell therapy, gene therapy and vaccine applications. Situated within VectorBuilder’s GMP facilities, the center will feature Pall’s small-scale iCELLis™ Nano and clinical-scale iCELLis 500+ bioreactors. This integration of the companies’ technical knowledge and advanced instrumentation will ensure a technology platform for continuous CDMO-process optimization.
“VectorBuilder has built 100,000 square feet of GMP facilities and launched a comprehensive CDMO portfolio for the production of gene therapy drugs and vector-based vaccines to meet the explosive demand for GMP products in the gene delivery space,” said Dr. Bruce Lahn, chief scientist at VectorBuilder. “As we rapidly expand from a pure research focus into the clinical market, this partnership will help the company to create optimized, efficient and automated GMP manufacturing platforms. This will strengthen VectorBuilder’s position as a global leader in custom GMP-grade viral vector manufacturing.”
Dr. Clive Glover, general manager of gene therapy at Pall, added: “We are very pleased to support VectorBuilder as the demand for GMP gene-delivery solutions continues to grow. Pall’s broad portfolio uniquely supports these processes with versatile upstream, downstream and fluid handling solutions, and we are happy to share our knowledge to help VectorBuilder develop a new generation of efficient, industrial-scale viral vector manufacturing processes.”
About VectorBuilder Inc.
VectorBuilder is a rapidly growing biotechnology company specializing in advanced genetic-engineering solutions for research and medicine. VectorBuilder is the global leader in gene delivery that covers a range of products and services, including vector design and optimization, vector cloning, virus packaging, library construction and screening, stable cell line generation, vector optimization (e.g., capsid evolution) and vector biodistribution analysis using animal models including nonhuman primates (NHPs) and GMP manufacturing of clinical-grade plasmids, mRNAs, proteins, viruses and cell lines. VectorBuilder's provides a revolutionary, online platform for designing and ordering custom vectors available at VectorBuilder.com. This award-winning platform has become highly popular with researchers around the world and has become an industry standard for its rich functionalities, extensive experimental validations and easy-to-use graphical interface. By leveraging the popularity of this platform, VectorBuilder has built a comprehensive portfolio that covers virtually all gene-delivery needs from bench to bedside.
About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit Pall.com.